Shares of Hims & Hers Health Inc. have roughly doubled over the past year — and Chief Executive Andrew Dudum cashed in on the ...

Hims & Hers Health is upgraded to a speculative Buy after a 20% drop, with growth potential in GLP-1 sales outweighing key ...

Hims & Hers has been an incredible stock to own over the last few years, making shareholders rich. It has $2 billion in ...

We recently published 10 Stocks That Vanished in Value Hims & Hers Health, Inc. (NYSE:HIMS) is one of the worst-performing stocks on Tuesday. Shares of telehealth company Hims & Hers Health dropped by ...

HIMS records subscriber surge and revenue growth in second-quarter 2025, but rising costs strain gross margins.

The healthcare company is experiencing excellent sales growth, but investors are concerned about its longer-term prospects.

Hims & Hers Health ( NYSE: HIMS) shares traded lower for the second straight session on Tuesday after the telehealth firm’s ...

Hims & Hers continues to spend heavily on marketing to attract new customers. During the quarter, its marketing spending ...

At $13.6 billion in market capitalization, Hims & Hers stock costs a pricey 70 times trailing earnings. It's even more ...

What Happened: According to a Form 4 filing with the U.S. Securities and Exchange Commission on Monday, Dudum sold 660,000 shares of Hims & Hers Health. The total transaction value is $33,384,120. The ...

The telehealth-consultation platform posted an increase in profit and revenue for the second quarter on growth in subscribers ...

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Hims & Hers Health wasn’t one of them. The 10 stocks that made the cut ...